Relugolix
Combination
Tablet

Relugolix Combination Tablet* consists of relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg. Relugolix Combination Tablet is under investigation for the treatment of endometriosis and for the prevention of pregnancy.

*tablet is the intended commercial presentation based on pharmaco-equivalence data with relugolix combination therapy (co-administration of relugolix 40 mg with estradiol 1.0 mg and norethindrone acetate 0.5 mg)

Relugolix Combination Tablet is not
approved by the FDA in endometriosis and
prevention of pregnancy.

How it works

As a GnRH receptor antagonist, relugolix binds to and blocks the GnRH receptor in the anterior pituitary gland.

Blocking GnRH receptors decreases the release of gonadotropins – luteinizing hormone (LH) and follicle-stimulating hormone (FSH) – thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women.

Clinical trial results

Relugolix Combination Tablet is not approved by the FDA in endometriosis and prevention of pregnancy.

Endometriosis

Our Phase 3 clinical program for endometriosis consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with pain associated with endometriosis. Eligible women who completed the SPIRIT 1 or SPIRIT 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women receive relugolix combination tablet for an additional 80-week period, resulting in a total treatment period of up to 104 weeks, designed to evaluate the safety and sustained efficacy of longer-term treatment.

Explore our pipeline

You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.